GR3017597T3 - Use of interleukin-10 in adoptive immunotherapy of cancer. - Google Patents
Use of interleukin-10 in adoptive immunotherapy of cancer.Info
- Publication number
- GR3017597T3 GR3017597T3 GR950402710T GR950402710T GR3017597T3 GR 3017597 T3 GR3017597 T3 GR 3017597T3 GR 950402710 T GR950402710 T GR 950402710T GR 950402710 T GR950402710 T GR 950402710T GR 3017597 T3 GR3017597 T3 GR 3017597T3
- Authority
- GR
- Greece
- Prior art keywords
- interleukin
- tils
- cancer
- adoptive immunotherapy
- tumor
- Prior art date
Links
- 102000003814 Interleukin-10 Human genes 0.000 title abstract 5
- 108090000174 Interleukin-10 Proteins 0.000 title abstract 5
- 229940076144 interleukin-10 Drugs 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract 5
- 102000000588 Interleukin-2 Human genes 0.000 abstract 4
- 108010002350 Interleukin-2 Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64134291A | 1991-01-16 | 1991-01-16 | |
| PCT/US1992/000067 WO1992012726A1 (en) | 1991-01-16 | 1992-01-15 | Use of interleukin-10 in adoptive immunotherapy of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3017597T3 true GR3017597T3 (en) | 1996-01-31 |
Family
ID=24571960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR950402710T GR3017597T3 (en) | 1991-01-16 | 1995-10-02 | Use of interleukin-10 in adoptive immunotherapy of cancer. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5776451A (el) |
| EP (2) | EP0567586B1 (el) |
| JP (1) | JPH06505250A (el) |
| CN (1) | CN1063308A (el) |
| AT (1) | ATE124866T1 (el) |
| AU (1) | AU1273992A (el) |
| DE (1) | DE69203443T2 (el) |
| DK (1) | DK0567586T3 (el) |
| ES (1) | ES2074879T3 (el) |
| GR (1) | GR3017597T3 (el) |
| IE (1) | IE68836B1 (el) |
| IL (1) | IL100667A0 (el) |
| MX (1) | MX9200161A (el) |
| MY (1) | MY108267A (el) |
| NZ (1) | NZ241321A (el) |
| WO (1) | WO1992012726A1 (el) |
| ZA (1) | ZA92304B (el) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW381026B (en) * | 1993-01-13 | 2000-02-01 | Schering Corp | Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells |
| JPH09508116A (ja) * | 1994-01-20 | 1997-08-19 | シェーリング コーポレイション | 末梢血単核細胞溶解活性を刺激するためのｉｌ−１０の使用 |
| US5770190A (en) * | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
| WO1997031532A1 (en) * | 1996-02-28 | 1997-09-04 | University Of Medicine & Dentistry Of New Jersey | Antisense interleukin 10 and methods of use |
| CA2264548A1 (en) | 1996-08-30 | 1998-03-05 | Human Genome Sciences, Inc. | Interleukin-19 |
| CA2380111A1 (en) * | 1999-08-03 | 2001-02-08 | Smith & Nephew, Inc. | Controlled release implantable devices |
| BR0113906A (pt) | 2000-09-14 | 2004-12-07 | Beth Israel Hospital | Modulação de respostas de células t mediadas por il-2 e il-15 |
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| CA2515779A1 (en) | 2003-02-14 | 2004-09-02 | The Curators Of The University Of Missouri | Contraceptive method and compositions related to proteasomal interference |
| US7294262B2 (en) * | 2003-08-27 | 2007-11-13 | Sta-Rite Industries, Llc | Modular fluid treatment apparatus |
| NZ597098A (en) | 2006-09-28 | 2013-05-31 | Merck Sharp & Dohme | Use of pegylated il-10 to treat cancer |
| US20080089875A1 (en) * | 2006-10-13 | 2008-04-17 | Zheng Cui | Methods and compositions for the treatment of cancer |
| CN102325790A (zh) | 2008-12-03 | 2012-01-18 | 西马生物医学计划公司 | 应用酚可溶性调控蛋白研制疫苗 |
| RU2549702C2 (ru) | 2008-12-17 | 2015-04-27 | Мерк Шарп И Доум Корп., | Получение и применение моно- и ди-пэг il-10 |
| CA2750922A1 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-key hybrid peptides that modulate the immune response to influenza |
| WO2011064398A1 (en) | 2009-11-30 | 2011-06-03 | Biotest Ag | Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) |
| WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
| EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
| EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
| AU2014281828B2 (en) | 2013-06-17 | 2019-05-09 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| JP6509867B2 (ja) | 2013-08-30 | 2019-05-08 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためにインターロイキン−１０を使用する方法 |
| MX2016005614A (es) | 2013-11-01 | 2016-12-09 | Spherium Biomed S L | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. |
| ES2862139T3 (es) | 2013-11-11 | 2021-10-07 | Armo Biosciences Inc | Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos |
| AU2015222917A1 (en) | 2014-02-27 | 2016-09-15 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
| US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| KR20170068553A (ko) | 2014-10-14 | 2017-06-19 | 아르모 바이오사이언시스 인코포레이티드 | 인터류킨-15 조성물 및 이의 용도 |
| US10143726B2 (en) | 2014-10-22 | 2018-12-04 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| CA2986755A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| JP6838004B2 (ja) | 2015-06-11 | 2021-03-03 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| EP3341012A4 (en) | 2015-08-25 | 2019-03-20 | Armo Biosciences, Inc. | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
| WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
| WO2019143883A2 (en) * | 2018-01-18 | 2019-07-25 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
| EP3844169A4 (en) | 2019-08-16 | 2021-12-15 | Applied Molecular Transport Inc. | COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKINS |
| CN110669139A (zh) * | 2019-09-18 | 2020-01-10 | 沣潮医药科技（上海）有限公司 | 二聚体免疫粘附素、药物组合物和用途 |
| CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
| CN114805538B (zh) * | 2022-05-20 | 2023-06-09 | 广州智瓴生物医药有限公司 | 一种增强til功效的培养方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| JPH0751496B2 (ja) * | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
| US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| AU4485089A (en) * | 1988-10-21 | 1990-05-14 | Brigham And Women's Hospital | Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr |
| WO1990010059A1 (en) * | 1989-02-21 | 1990-09-07 | Terumo Corporation | A process for the generation of proliferating cd4 lymphocytes |
| IL94878A (en) * | 1989-06-28 | 2003-01-12 | Schering Corp | Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same |
-
1992
- 1992-01-15 AT AT92905179T patent/ATE124866T1/de not_active IP Right Cessation
- 1992-01-15 JP JP4505288A patent/JPH06505250A/ja active Pending
- 1992-01-15 ZA ZA92304A patent/ZA92304B/xx unknown
- 1992-01-15 DK DK92905179.5T patent/DK0567586T3/da active
- 1992-01-15 IL IL100667A patent/IL100667A0/xx unknown
- 1992-01-15 EP EP92905179A patent/EP0567586B1/en not_active Expired - Lifetime
- 1992-01-15 IE IE920113A patent/IE68836B1/en not_active IP Right Cessation
- 1992-01-15 DE DE69203443T patent/DE69203443T2/de not_active Expired - Fee Related
- 1992-01-15 EP EP92300331A patent/EP0495639A1/en active Pending
- 1992-01-15 MY MYPI92000065A patent/MY108267A/en unknown
- 1992-01-15 ES ES92905179T patent/ES2074879T3/es not_active Expired - Lifetime
- 1992-01-15 MX MX9200161A patent/MX9200161A/es unknown
- 1992-01-15 AU AU12739/92A patent/AU1273992A/en not_active Abandoned
- 1992-01-15 WO PCT/US1992/000067 patent/WO1992012726A1/en active IP Right Grant
- 1992-01-16 NZ NZ241321A patent/NZ241321A/en unknown
- 1992-01-16 CN CN92100319A patent/CN1063308A/zh active Pending
-
1994
- 1994-07-05 US US08/270,805 patent/US5776451A/en not_active Expired - Fee Related
-
1995
- 1995-10-02 GR GR950402710T patent/GR3017597T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX9200161A (es) | 1992-07-01 |
| JPH06505250A (ja) | 1994-06-16 |
| ZA92304B (en) | 1992-09-30 |
| ATE124866T1 (de) | 1995-07-15 |
| US5776451A (en) | 1998-07-07 |
| IE68836B1 (en) | 1996-07-10 |
| NZ241321A (en) | 1997-06-24 |
| CN1063308A (zh) | 1992-08-05 |
| IE920113A1 (en) | 1992-07-29 |
| AU1273992A (en) | 1992-08-27 |
| EP0567586A1 (en) | 1993-11-03 |
| DE69203443T2 (de) | 1995-12-07 |
| MY108267A (en) | 1996-09-30 |
| ES2074879T3 (es) | 1995-09-16 |
| EP0495639A1 (en) | 1992-07-22 |
| EP0567586B1 (en) | 1995-07-12 |
| WO1992012726A1 (en) | 1992-08-06 |
| DK0567586T3 (da) | 1995-12-04 |
| DE69203443D1 (de) | 1995-08-17 |
| IL100667A0 (en) | 1992-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA92304B (en) | Use of interleukin-10 in adoptive immunotherapy of cancer | |
| Niederwieser et al. | IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. | |
| Suda et al. | Growth-promoting activity of IL-1 alpha, IL-6, and tumor necrosis factor-alpha in combination with IL-2, IL-4, or IL-7 on murine thymocytes. Differential effects on CD4/CD8 subsets and on CD3+/CD3-double-negative thymocytes. | |
| Rook et al. | The immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sézary T cells | |
| AU6834990A (en) | Cytotoxic lymphocyte maturation factor and monoclonal antibodies directed thereto | |
| EP0211769A3 (en) | Adoptive immunotherapy as a treatment modality in humans | |
| EP0668781A4 (en) | THERAPY OF CANCER BY THE GENE OF LYMPHOKINE. | |
| ZA967756B (en) | Adoptive immunitherapy using macrophages sensitized with heat shock protein-epitope complexes | |
| DK0789588T3 (da) | Metode til fremstilling af et medikament til behandling af sekundær immundefekt | |
| PH19584A (en) | A method for purification of recombinant mature human interleukin-2 | |
| Talmadge et al. | Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes | |
| AU4156389A (en) | T helper cell growth factor | |
| Flynn et al. | Production of interleukin-1 and interleukin-2 in allogeneic mixed lymphocyte cultures under copper, magnesium and zinc deficient conditions | |
| AU6006090A (en) | A method of increasing adenosine excretion | |
| HUT56721A (en) | Process for producing pharmaceutical compositions suitable for treating cancer of pleura | |
| NZ224116A (en) | Compositions of interleukin-2 and fk565; method of stimulation of the immune system and package | |
| Dupuy | Does atopic dermatitis result from cytokine dysregulation? | |
| AU2925789A (en) | Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection | |
| Lacerna Jr et al. | Adoptive cancer immunotherapy utilizing lymphokine activated killer cells and gamma interferon activated killer monocytes | |
| YU4792A (sh) | Postupak gajenja tumornih infiltirajućih limfocita | |
| EP0303483A3 (en) | Novel lymphokine and compositions thereof | |
| Okamura et al. | The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro | |
| Whiteside | The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2 | |
| Lindemann et al. | Interleukin-2 in the Treatment of Malignant Melanoma and Renal Cell Carcinoma | |
| GB8729410D0 (en) | Method for production of lymphokine activated killer(lak)cells & lak cells so produced |